# Resia Pretorius Microclots: Who Is Behind the Research?

> Resia Pretorius microclots explained: who she and Douglas Kell are, who their co-authors are, and what each key paper reported, plus who disagrees.

Canonical: https://amyloid-test.com/resources/resia-pretorius-microclots/
Last updated: 2026-11-18
Author: Tim Ottowitz

**Short answer:** The research on fibrin amyloid microclots comes mainly from Prof Etheresia "Resia" Pretorius at Stellenbosch University and Prof Douglas Kell at the University of Liverpool, with clinician co-authors such as Dr Jaco Laubscher of Mediclinic Stellenbosch. Their papers on amyloid-like fibrin clotting date from 2016. Cochrane reviewers and other haematologists dispute what the particles mean for Long COVID.

## Key takeaways

- Pretorius and Kell began publishing on amyloid-like fibrin clotting in 2016, before COVID-19.
- The Long COVID microclot papers are small observational studies, typically with tens of participants.
- A Liverpool group led by Schofield and Toh reported microclots in ICU patients, a separate line of work.
- A 2023 Cochrane review found the laboratory evidence insufficient to link the particles to Long COVID.
- Pretorius is named as a director of Biocode Technologies, a microclot-testing spin-out, in a 2023 paper's competing-interest statement.

Fibrin amyloid microclot research comes mainly from Prof Resia Pretorius (Stellenbosch University, South Africa) and Prof Douglas Kell (University of Liverpool, UK), working with clinicians and students. This page lists who they are, who co-authored the key papers, what each paper reported and who disagrees. Everything here comes from the papers and university or ORCID profiles linked below.

## Who is Resia Pretorius?

Etheresia "Resia" Pretorius is a Distinguished Professor in Physiological Sciences at Stellenbosch University. Her [ORCID record](https://orcid.org/0000-0002-9108-2384) and a 2025 profile on The Conversation list her in that post. The profile adds that she is an Honorary Professor at the University of Liverpool and that her work covers how inflammatory molecules interact with clotting proteins, platelets and blood cells.

Her 2021 Long COVID paper lists her under the Department of Physiological Sciences at Stellenbosch. The 2023 Heliyon paper's competing-interest statement names her as a director of Biocode Technologies, a company that offers microclot testing. That's a disclosure, not a criticism, and it's worth knowing when you read the papers.

## Who is Douglas Kell?

Douglas Kell is Research Chair in Systems Biology at the University of Liverpool. His [university profile](https://www.liverpool.ac.uk/people/douglas-kell) says he studied biochemistry at Oxford, later worked at Aberystwyth and Manchester, and came to Liverpool in December 2018. He describes himself as a systems biologist. He is a co-author on most of the papers in the table below.

## Who are the clinician collaborators?

The 2022 Biochemical Journal review lists its authors as Kell (University of Liverpool), Dr Jaco Laubscher (Mediclinic Stellenbosch) and Pretorius. Laubscher is also an author on the 2020, 2021 and 2025 papers below. Biocode's website lists a microclot testing centre at Mediclinic Stellenbosch under Dr Jaco Laubscher.

Other co-authors named in affiliations include Mare Vlok, who works in mass spectrometry at Stellenbosch University, and Dr Asad Khan of Manchester University Hospitals, who appears on the 2023 and 2024 papers. The 2025 NETs paper was led by Alain Thierry's group at the Montpellier Cancer Research Institute, with Stellenbosch co-authors, Laubscher, Kell and Pretorius.

## What did each key paper report?

| Year | Paper | Journal | What it reported | Study type and size |
|---|---|---|---|---|
| 2016 | Pretorius et al., LPS and anomalous clotting | J R Soc Interface | Tiny amounts of bacterial LPS added to healthy donors' blood and plasma changed fibrin fibres into an amyloid-like form | Lab study, healthy donor blood and plasma |
| 2017 | Kell and Pretorius, "Proteins behaving badly" | Prog Biophys Mol Biol | Argued that anomalous fibrin in several diseases amounts to amyloidogenesis | Review |
| 2017 | Pretorius et al., type 2 diabetes | Cardiovasc Diabetol | Plasma clotting in type 2 diabetes was amyloid in nature by Thioflavin T and Amytracker stains | Lab study, 33 with T2D and 34 healthy people |
| 2018 | Pretorius et al., Parkinson's disease | PLoS ONE | Fibrin amyloid state seen in Parkinson's plasma and reversed by LBP in vitro | Lab study, 26 with Parkinson's and 19 healthy people |
| 2020 | Pretorius et al., COVID-19 and T2DM | Cardiovasc Diabetol | Microclots in native plasma, higher in COVID-19 than in T2DM | Preliminary report, 20 COVID-19, 10 T2DM, 10 healthy |
| 2021 | Grobbelaar et al., spike protein S1 | Biosci Rep | Spike S1 added to healthy plasma altered fibrin(ogen) and resisted trypsin digestion; see [spike and fibrinolysis](https://amyloid-test.com/resources/spike-protein-amyloid-fibrils-fibrinolysis/) | In vitro (lab dish) |
| 2021 | Pretorius et al., Long COVID | Cardiovasc Diabetol | Large amyloid deposits in Long COVID plasma, resistant to fibrinolysis | Observational, 11 Long COVID, 15 acute COVID-19, 10 T2DM, 13 healthy |
| 2022 | Kell, Laubscher and Pretorius | Biochem J | Proposed a central role for microclots in Long COVID; see [the research summary](https://amyloid-test.com/resources/fibrin-amyloid-microclots-research/) | Review and hypothesis |
| 2022 | Nunes et al., ME/CFS | Pharmaceuticals | Microclot area often over 10-fold greater than in controls, but lower than in Long COVID; see [ME/CFS and microclots](https://amyloid-test.com/resources/microclots-me-cfs/) | Observational, 25 ME/CFS and 15 healthy |
| 2023 | Turner et al., flow cytometry | Heliyon | Imaging flow cytometry showed higher microclot concentration and size in Long COVID | Observational, 40 Long COVID and 20 healthy |
| 2024 | Kell, Khan and Pretorius | Res Pract Thromb Haemost | Reply to the Hunt et al. critique | Letter |
| 2025 | Thierry et al., NETs | J Med Virol | NET markers were associated with microclot size and number; see [microclots and NETs](https://amyloid-test.com/resources/microclots-nets-long-covid/) | Observational |

The pre-COVID row matters for the question "who discovered microclots". The 2016 to 2018 papers described amyloid-like fibrin before the pandemic. The COVID-19 and Long COVID papers applied the same staining approach. For what the particles are, see [what microclots are](https://amyloid-test.com/resources/what-are-microclots/) and the [Long COVID summary](https://amyloid-test.com/resources/amyloid-microclots-long-covid/).

## What does fibrinaloid mean?

Fibrinaloid means fibrin in an amyloid form. In their 2022 Biochemical Journal review, Kell, Laubscher and Pretorius wrote that, to avoid ambiguity, they considered it sensible to refer to such fibrin-based amyloids as fibrinaloids. We found no earlier use in Europe PMC, so "proposed in 2022" is the safe wording.

## Who else has studied microclots?

A Liverpool group not led by Pretorius or Kell used the same Thioflavin T method on platelet-poor plasma. In Blood Advances in 2024, Schofield, Toh and colleagues studied 104 intensive care patients and 20 healthy controls. They found microclots in 44 patients (42.3%) at admission and in none of the controls, and they linked high counts to disseminated intravascular coagulation and 28-day mortality.

That study concerned critically ill patients, not Long COVID, and it used a staining method similar to Pretorius's. The 2025 NETs paper included Montpellier authors, as noted above.

## Who disagrees, and why?

The 2023 Cochrane review (Fox, Hunt, Ariëns and colleagues) identified five laboratory studies. It reported particles in people with the condition, healthy people and people with diabetes, and judged the results insufficient to support an association with Long COVID. It found no randomised trials of plasmapheresis for this purpose.

Hunt and colleagues repeated that view in a 2024 editorial in Research and Practice in Thrombosis and Haemostasis, and Kell, Khan and Pretorius replied in the same journal. A further 2024 exchange of letters, with Connors and Ariëns responding to Kell and colleagues, carries a title that calls the roles of anticoagulation and microclots uncertain. We've read only the titles of those letters, so we don't summarise their arguments here. The wider debate is covered in [are microclots real](https://amyloid-test.com/resources/are-microclots-real/) and [microclots versus ordinary blood clots](https://amyloid-test.com/resources/microclots-vs-blood-clots/).

## Can the public get tested through Pretorius's lab?

Her university work is research. Biocode Technologies, described in a Stellenbosch University article as a spin-out that licenses its microclot test to labs and clinics, lists bookings on its website that need the name of a referring doctor. For other options, see our [directory of microclot testing labs](https://amyloid-test.com/resources/microclot-testing-labs-treatment-centers/) and [how microclots are tested](https://amyloid-test.com/resources/how-to-test-for-microclots/). A treatment hypothesis from the same authors is covered in [triple therapy for Long COVID](https://amyloid-test.com/resources/triple-therapy-long-covid/); that decision belongs with your clinician.

## Where does our test fit?

Our [amyloid test](https://amyloid-test.com/) uses the same staining principle, Thioflavin T fluorescence microscopy, as this published research. We have no affiliation with these researchers, and our dried finger-prick method has not been validated against their venous platelet-poor plasma method.

If you have sudden chest pain, severe breathlessness, one-sided weakness, confusion or a swollen painful leg, seek emergency care. These can signal a large clot or stroke, and no microclot result changes that.

## FAQ

### Who discovered microclots?

Researchers at Stellenbosch University and the University of Liverpool, led by Resia Pretorius and Douglas Kell, reported amyloid-like anomalous fibrin clotting in diseases such as type 2 diabetes from 2016. They described it in COVID-19 plasma in 2020 and in Long COVID in 2021. Other groups later used the same staining method, and critics dispute what the findings mean.

### Who is Resia Pretorius?

Etheresia "Resia" Pretorius is a Distinguished Professor in Physiological Sciences at Stellenbosch University, South Africa, according to her ORCID record and a 2025 profile on The Conversation. A 2025 profile also lists her as Honorary Professor at the University of Liverpool. Her group studies how inflammatory molecules interact with clotting proteins, platelets and blood cells.

### Who is Douglas Kell?

Douglas Kell is Research Chair in Systems Biology at the University of Liverpool, where he joined in December 2018, according to his university profile. He is a systems biologist who studied biochemistry at Oxford. He has co-authored most of the fibrin amyloid microclot papers with Pretorius, usually as senior or corresponding author.

### What does fibrinaloid mean?

Fibrinaloid is shorthand for fibrin that has taken an amyloid form. Kell, Laubscher and Pretorius proposed it in a 2022 review to avoid ambiguity, writing that they considered it sensible to call these fibrin-based amyloids fibrinaloids. Fibrinaloid microclots and fibrin amyloid microclots are used for the same particles.

### Does Resia Pretorius offer microclot testing to the public?

Testing in her university lab is research-based. A separate company, Biocode Technologies, a Stellenbosch University spin-out, lists microclot test bookings with a referring doctor on its website, including at Mediclinic Stellenbosch. Pretorius is named as a director of Biocode in a 2023 paper. For other options see our directory of labs and centres.

## Sources

- [Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide](https://doi.org/10.1098/rsif.2016.0539) (Journal of The Royal Society Interface, 2016)
- [Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting](https://doi.org/10.1016/j.pbiomolbio.2016.08.006) (Progress in Biophysics and Molecular Biology, 2017)
- [Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains](https://doi.org/10.1186/s12933-017-0624-5) (Cardiovascular Diabetology, 2017)
- [Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease](https://doi.org/10.1371/journal.pone.0192121) (PLoS ONE, 2018)
- [Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report](https://doi.org/10.1186/s12933-020-01165-7) (Cardiovascular Diabetology, 2020)
- [SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19](https://doi.org/10.1042/BSR20210611) (Bioscience Reports, 2021)
- [Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin](https://doi.org/10.1186/s12933-021-01359-7) (Cardiovascular Diabetology, 2021)
- [A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications](https://doi.org/10.1042/BCJ20220016) (Biochemical Journal, 2022)
- [The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)](https://doi.org/10.3390/ph15080931) (Pharmaceuticals, 2022)
- [Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model](https://doi.org/10.1016/j.heliyon.2023.e19605) (Heliyon, 2023)
- [Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition](https://doi.org/10.1002/14651858.CD015775) (Cochrane Database of Systematic Reviews, 2023)
- [Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality](https://doi.org/10.1182/bloodadvances.2023012473) (Blood Advances, 2024)
- [Challenging the current hypothesis that thrombosis is responsible for the post-COVID-19 condition](https://doi.org/10.1016/j.rpth.2024.102442) (Research and Practice in Thrombosis and Haemostasis, 2024)
- [Fibrinaloid microclots in long COVID: assessing the actual evidence properly](https://doi.org/10.1016/j.rpth.2024.102566) (Research and Practice in Thrombosis and Haemostasis, 2024)
- [Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients](https://doi.org/10.1002/jmv.70613) (Journal of Medical Virology, 2025)

## Related

- [What Are Amyloid Microclots? Definition, Causes and Evidence](https://amyloid-test.com/resources/what-are-microclots/)
- [How to Test for Microclots: Methods, Labs and Limits](https://amyloid-test.com/resources/how-to-test-for-microclots/)
- [Micro Blood Clots Symptoms: Microclots Symptoms Guide](https://amyloid-test.com/resources/microclots-symptoms-guide/)
